CN1174032A - Compound vitamin drop for infant - Google Patents

Compound vitamin drop for infant Download PDF

Info

Publication number
CN1174032A
CN1174032A CN 96109176 CN96109176A CN1174032A CN 1174032 A CN1174032 A CN 1174032A CN 96109176 CN96109176 CN 96109176 CN 96109176 A CN96109176 A CN 96109176A CN 1174032 A CN1174032 A CN 1174032A
Authority
CN
China
Prior art keywords
infant
drop
vitamin
gla
dha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 96109176
Other languages
Chinese (zh)
Other versions
CN1094348C (en
Inventor
余善铭
康文宇
赵镭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SANMING BIOENGINEERING CO Ltd BEIJING
Original Assignee
SANMING BIOENGINEERING CO Ltd BEIJING
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SANMING BIOENGINEERING CO Ltd BEIJING filed Critical SANMING BIOENGINEERING CO Ltd BEIJING
Priority to CN96109176A priority Critical patent/CN1094348C/en
Publication of CN1174032A publication Critical patent/CN1174032A/en
Application granted granted Critical
Publication of CN1094348C publication Critical patent/CN1094348C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention relates to compound vitamin drop for infant, especially compound vijt and unsaturated fatty acid drop. The said drop can make up daily required vitamin A, vitamin D and unsaturated fatty acids, and it may replace available marketable vitamins A and D drop. In addition, it can provide infant with GLA and DHA essential for infant growth and easy to lack in body.

Description

Compound vitamin drop for infant
What the present invention relates to is a kind of compound vitamin drop for infant, and concretely, what the present invention relates to is a kind of vitamin and the compound infant special product of unsaturated fatty acid (LA, GLA, DHA, α LA), and two kinds of dosage forms of soft capsule drop and Emulsion are arranged.
Existing result of study shows that vitamin A, D have important effect for infant growth fertility, and infant can not get the supply of competent vitamin A, D from diet.Therefore, must use vitamin A, D drop after the birth, dosage commonly used is proposed by the research worker of many countries.
Long-chain, polyene unsaturated fatty acid have also been affirmed in the further investigation of prior art, and for example n6, n3 are that jeceric acid (GLA, α LA) and n3 are docosahexenoic acid (DHA), are essential for infant growth.
But the vitamin of prior art and unsaturated fatty acid all are single uses, and the cooperative effect between these two fails to fully play.
The object of the present invention is to provide a kind of three ring compound vitamin drop for infant, concretely, is a kind of special product of being used by vitamin and the compound infant of polyene unsaturated fatty acid; Product of the present invention has overcome the shortcoming of prior art.
Purpose of the present invention can be achieved in the following manner:
With vitamin A and/or D, cooperate unsaturated fatty acid, adopt existing processes to become soft capsule drop or Emulsion.
Comprehensive from existing theory, and preliminary experiment and observation, performance that can basic confirmation joint product of the present invention is better than the effect of independent use.
By following elaborating, can further understand compound vitamin drop for infant formulation principle of the present invention, function, effect.
Employed various raw materials are as follows among the present invention:
1, vitamin A, D: other vitamin A of pharmaceutical grade, the vitamin D of selecting to meet the state-promulgated pharmacopoeia regulation;
2, n6 and n3 are jeceric acid (GLA, α LA): select the mycelium dry powder of three ring bio-engineering corporation fermenting and producing for use or with seed of Radix Oenotherae erythrosepalae, borage seed etc. through CO 2Supercritical extraction, further refining again and get;
3, fish oil: because the ratio of breast milk DHA: EPA is 4: 1~5: 1, so special-purpose fish oil, wherein DHA: the EPA=5 of baby that we have selected for use end scholar Roche Holding Ag to produce when material choice: 1.
One, product introduction:
This product is coarse at the product of traditional VA, VD class preparation soft gelatin capsule or drop, and VA, that the VD ratio is provided with is improper, mostly VA, VD=10: 1, there is VA.Capsule materials such as VD ball are hard, and infant can't be swallowed.And drop packing to be 10ml mostly mould bottle for a short time or the glass bottle is joined suction pipe, poorly sealed, reveal easily, open back one or two months just can take shortcoming such as suction pipe uses easy pollution repeatedly, and drop is easily oxidated and in addition improved.
Ah VA, the VD class supplementing preparation of research worker imagination Development of New Generation.It has designed the product of two kinds of specifications and two kinds of dosage forms at all ages and classes section infant.
A kind of is the soft capsule drop, and olive-type has a little projection, cuts off front projection, and extruding can directly splash into content in the infant mouth or add in the liquid food such as year milk and take.
Another kind is an O/W type Emulsion, for oral or band scale are moulded bottled.And on prescription except that the VA, the VD that add suitable dosage, also added docosahexenoic acid (DHA), n6 and n3 are jeceric acid (GLA, α LA) and linoleic acid (LA).
Can not only replenish VA, the VD that needs in the infant growth with regard to product of the present invention like this, prevent it to lack, and n6 and n3 can also be provided simultaneously is important polyunsaturated fatty acid.LA is an essential fatty acid, α LA is appealed to establish the status that it must unsaturated fatty acid by many nutritionists in recent years, they are respectively n6 and the metabolic predecessor of n3 series fatty acid, GLA and DHA then are the materials that has important physiologically active in its metabolite, and educating especially to infant growth, the growth of cranial nerve and visual system plays an important role; Particularly the stage of infant brain development most critical is that mother's last trimester of pregnancy is to being born 18 months; Stop when general two years old or three years old; And this stage be infant build phase apace, the shortage of VA, VD easily takes place.Therefore replenishing VA, VD and n6, n3 simultaneously in this stage is that polyunsaturated fatty acid (GLA, aLA, DHA) has significance.
Two, formula for a product:
1, soft capsule drop
Prescription: every seed lac ball loading amount 0.5-0.7ml mixotrophism oil, wherein: Radix Oenotherae erythrosepalae oil or with GLA oil V A0-1 year baby 150~750l μ Oleum Radix Arnebiae (Oleum Radix Lithospermi) mixes 60~80% 1-3 year baby, 250~1000l μ fish oil, 10~30% V D0-1 baby 100~250l μ
1-3 year baby 100~300l μ Oleum Hippophae 0~10% V E0.05~2.0mg
Taking dose, twice, one time on the one ball
Day is replenished VA, VD and polyunsaturated fatty acid amount (i.e. two seed lac ball nutrition total amounts)
The LA of n6 series and GLA 300~1000mg
The α LA of n3 series, DHA 50~200mg
V A0-1 year baby 300~1500l μ
1-3 year baby 500~2000l μ
V DThe child 200-700l μ in 0-1 year baby 200~500l μ 1-3 year
V E0.1~4.0mg 0/W type Emulsion
The 10ml ampere is bottled or be with scale to mould bottle, joins suction pipe.
Prescription: V A, V DUnsaturated fatty acid miscella 1~10%;
90-99% such as high fructose syrup, fruit juice, thickening agent, emulsifying agent;
Radix Oenotherae erythrosepalae oil in the miscella (or mix with Oleum Radix Arnebiae (Oleum Radix Lithospermi), soybean oil, GLA oil) 60~80%;
Fish oil 10~30%; Oleum Hippophae 0~10%;
Taking dose, twice, one time on the one 5~10ml;
Day extra-nutrition amount:
The LA of n6 series and G LA 300-1000mg;
The α LA of n3 series, DHA 50-200mg;
V A0-1 year baby 300-1500l μ
1-3 year child 500-2000l μ
V D0-1 year baby 200-500l μ
1-3 year child 200-700l μ
V E0.1-4mg;
Dispensing information
V A, V D, V EBe fatsoluble vitamin, it is good that needs fat and biliary existence could absorb, and the fat that unsaturated double-bond is more and fusing point is lower is is more easily digested and assimilated.Many more its fusing points of polyunsaturated fatty acid and short-chain fatty acid are low more, easy more digestion.As fatsoluble vitamin V A, V D, V FWhen the fat absorption of carrier is bad, V A, V D, V EAbsorption also reduce.Therefore, we select the Radix Oenotherae erythrosepalae that is rich in polyunsaturated fatty acid (or with Oleum Radix Arnebiae (Oleum Radix Lithospermi), soybean oil, GLA) Oleum Hippophae and fish oil for use, are in harmonious proportion together as V by a certain percentage A, V D, carrier.Replenish V for infant on the one hand A, V D, E E, replenished the essential fatty acid of n6 and n3 series on the other hand again.The mixed oil fusing point is lower than soybean oil, Oleum Brassicae campestris, is easy to digest and assimilate.And V EAdding can not only prevent V A, and as the oils and fats of its carrier in external and intravital oxidation, can also promote V AAbsorption.
The quantitative basis of main component
Formulation principle of the present invention is according to the known result of study of prior art and fixed, wherein:
V A, V DAddition with reference to V A, V DDrop every day dose and Chinese Soclety of Nutrition's day quantity delivered of recommending consider other food sources, V DWith dose V AOr the dosage of the 50%-100% of recommended amounts adds.Not only can prevent and treat V A, V DShortage (the famine person can be shone doctor's advice, increase day a dosing); And can avoid V A, V DReplenish the excessive poisoning that causes because of originating in many ways, our principle is that suitable dosage is taken flexibly.
N6 is jeceric acid (GLA) and docosahexenoic acid (DHA).
Research worker is according to eutrophy, mother's of monophagia breast milk composition not, think that the 40mg/kg body weight is preferably as the day quantity delivered of infant arachidonic acid and other n-6 series fatty acid [as jeceric acid (GLA)], 20mg/kg is as the day quantity delivered of the docosahexenoic acid (DHA) of infant.
The day quantity delivered of calculating full-term newborn infant jeceric acid (GLA) thus is about 304mg, the quantity delivered of docosahexenoic acid (DHA) is about 152mg, though also do not have at present method that the full-term newborn infant this respect is carried out the evidence of strict random process experimentation, think whole nerve and the vision allelic potencies of performance that this can maximum possible.
Therefore, the quantity delivered of the jeceric acid in compound vitamin drop for infant of the present invention (GLA), 22 carbon acids (DHA) is selected the 20-50% of above recommended amounts for use, 20-99%, and maintenance n6 is that fatty acid/n3 is that fatty acid is between 3-10.
This dosage can satisfy the demand of GLA, docosahexenoic acid (DHA) substantially for the baby of the not breast fed of firm birth.
Take this product, can make it absorb competent jeceric acid (GLA), docosahexenoic acid (DHA).
Its intake may reach or a little more than average level.For normal breast-fed babies, because at different times, the variation of wet nurse's diet and health, its milk component also can change, jeceric acid (GLA), docosahexenoic acid (DHA) Deficiency of Intake also may appear in certain period, take this formulation product, can make the intake of baby GLA, docosahexenoic acid (DHA) keep or sell being higher than average level, long-term a little higher than average level.
Can absorption cause untoward reaction to jeceric acid (GLA) docosahexenoic acid (DHA)? think that at present no, the excursion of jeceric acid (GLA), AA, the content of docosahexenoic acid (DHA) in breast milk is bigger, because the dietary habit difference makes in some countries and regions wet nurses' the milk docosahexenoic acid (DHA) or jeceric acid (GLA) be in higher level.And general untoward reaction does not appear in its children.
Though being arranged, report points out that the fish oil that is rich in jeceric acid (GLA), docosahexenoic acid (DHA) is used for clinical effect with anticoagulant, its bad one side is to prolong the bleeding time, cause excessive hemorrhage during wound, but the therapeutic dose of fish oil is bigger, reaches therapeutic dose level far away at this.
But this viewpoint lacks the support of argument, and more expert thinks that big taking dose can not cause as above ill effect.According to the Epidemiological study data, the Eskimos for each person every day intake be equivalent to W-3 fatty acid 5~10g keep basically all one's life.And the clinical trial multiselect is with this dosage (9), not just like last report.
Thereby, the jeceric acid in this recipe design (GLA), docosahexenoic acid (DHA) so amount be safe to 0~1 years old baby.
For firm wean infant, because the fat that breast milk provides accounts for total fatty intake greatly, though, can obtain certain supply by foods such as the meat of ingesting, egg, sugar and support, but the intake of total fat still can descend, and the shortage of unsaturated fatty acid takes place easily.
Can suitably alleviate total fat and take in the deficiency that unsaturated fatty acid is especially taken in by taking this product.
For 1-3 year child and since its diet in the absorption of linoleic acid, alpha-linolenic acid and body in enzyme system perfect, self can transform and obtain a certain amount of jeceric acid (GLA), docosahexenoic acid (DHA).Therefore, when component design, consider the part supply.
Be embodiments of the invention below, in an embodiment, the consumption of vitamin A .D is an iu; Wherein, DHA is a docosahexenoic acid; GLA is a jeceric acid.
Embodiment 1~7 is at 0-1 year baby
Embodiment 1 Embodiment 2 Embodiment 3 Embodiment 4 Embodiment 5 Embodiment 6 Embodiment 7
Vitamin A ??300-1500 ??300-1500 ???300-1500 ???300-1500 ??300-1500 ??300-1500 ??300-1500
Vitamin D ??200-500 ??200-500 ???200-500 ???200-500 ??200-500 ??200-500 ??200-500
??DHA(mg) ??100-120 ???80-90 ????60-70 ???70-80 ??90-100 ???40-60 ??120-150
??GLA(mg) ???70-80 ???80-90 ???100-110 ???90-100 ???60-70 ??110-130 ??130-160
Vitamin E (mg) ??0.1-4.0 ???0.1-4.0 ??0.1-4.0 ???0.1-4.0 ???0.1-4.0 ???0.1-4.0 ???0.1-4.0
At 1~3 years old child
Embodiment 8 Embodiment 9 Embodiment 10 Embodiment 11 Embodiment 12 Embodiment 13 Embodiment 14
Vitamin A ?500-2000 ?500-2000 ?500-2000 ?500-2000 ?500-2000 ?500-2000 ?500-2000
Vitamin D ?200-700 ?200-700 ?200-700 ?200-700 ?200-700 ?200-700 ?200-700
??DHA(mg) 100-120 ??80-90 ??60-70 ??70-80 ??90-100 ??40-60 ?120-150
??GLA(mg) ???70-80 ??80-90 ?100-110 ??90-100 ??60-70 ?110-130 ?130-160
Vitamin E mg ??0.1-4.0 ?0.14.0 ?0.1-4.0 ?0.1-4.0 ?0.1-4.0 ?0.1-4.0 ?0.1-4.0
Prior art, or vitamin A .D drop series products in the market do not comprise polyunsaturated fatty acid usually, therefore can not satisfy the required nutrition of infant growth all sidedly
Therefore, drop of the present invention not only has the repertoire effect of vitamin A, D drop, but also has the effect of polyunsaturated fatty acid:
In infants, the y-linolenic acid that belongs to n-6 series unsaturated fatty acid is a structural material of forming each tissue biological's film, the physiology of pair cell plays important regulatory role, has tangible lipoid peroxidization resistant simultaneously, thereby alleviated cytolipin peroxidating infringement, had that data shows that GLA can show that Millefolium suppresses that the capillary permeability that multiple extremely scorching thing causes increases, inflammation is oozed out, edema and inflammation breed the granulation tissue hyperplasia of phase and play certain antiinflammatory action.
Other has experimental data to show, GLA metabolite AA level in vivo is low relevant with growth rate before the premature labor riveting production.AA has special function at aspects such as neural and vascular functions in addition, with the n-3 series fatty acid to wave coordinative role place (2).The supply of infant n-6 series unsaturated fatty acid has caused the great attention of world's nutrition circle.
Described linoleic acid is under the effect of infants endoenzyme, and then transformation turns to GLA, AA.
But in fact, supplying with under the competent linoleic situation, the as above symptom of n-6 series fatty acid still can occur lacking, its reason may be a various enzyme systems zoon not as yet in the baby germling, to such an extent as to the committed step that linoleic acid-GLA-AA (6) transforms, promptly linoleic acid-GLA transforms and is suppressed.Thereby be necessary to mend GLA and then be converted into AA, bring into play its a series of physiological action.
The DHA that belongs to the product satisfied fatty acid of n-3 row also plays an important role in infants, and DHA is present in grey matter, white matter, retina and other nervous tissue of human brain.DHA accounts for 10% in the brain group born of the same parents fat, except that participating in constituting the film lipid bilayer, also is present in the mitochondrion and the microsome of brain cell device, and the neurite contact.The DHA of capacity supplies with the brain development that helps fetus, brain cell propagation.
Replenish the attention that DHA has caused academia to infant, alpha-linolenic acid is added in the formulas in some country as the precursor of DHA, but the baby of edible formulas, some still has the phenomenon that lacks n-3 series unsaturated fatty acid to take place.Be presented at and urge the enzyme under-activity that alpha-linolenic acid is converted into DHA in the infants, be not enough to support DHA accumulation in tissue.
And a spot of DHA supplies with the DHA level raising that just can make in the infant blood plasma phospholipid in the product, and is more more effective than replenishing relatively large alpha-linolenic acid in the diet.In view of the above, the up-to-date recommendation guide for use of FAO/WHO is set forth, and all babies ' formula milk powders should contain DHA, and full-term newborn infant should be taken in per kilogram of body weight 20mg DHA every day, and the premature infant should take in per kilogram of body weight 40mg DHA every day.
N-6 and n-3 fatty acid are to the structure of film with as the precursor of eicosenoic acid and have the important physical effect, and they are chemical compounds of high activity.
Different eicosenoic acids has widely not same-action, has opposite effect sometimes, so the balance of the unsaturated fatty acid of n-3 that infant is taken in and n-6 series is sent out also extremely important for the normal growth of infant.
Have data to show, the ratio of the alpha-linolenic acid of the linoleic acid of n-6 series and n-3 series should be 5 in the meals: 1-10: between 1, it is generally acknowledged near 5: 1 the bests.
And because the dietary habit of China, in general, the intake of n-6 series unsaturated fatty acid is on the high side, and the DHA that this product replenishes a certain amount of n-3 series is useful for keeping this absorption ratio.
In compound vitamin drop for infant of the present invention, the antioxidant that prevents the polyunsaturated fatty acid oxidation that is adopted, the addition of synergist and interpolation add kind, can adopt in the prior art any suitable, the technical staff of the industry is after understanding detailed content of the present invention, just can determine that addition and interpolation add kind, thereby make product have the shelf-life in 1~2 year.
In sum, compound vitamin drop for infant of the present invention can replenish required sufficient vitamin A every day, D and an amount of polyunsaturated fatty acid, can substitute commercially available vitamin A, D drop at present fully; Simultaneously can provide infant growth needed, and be to be easier to the GLA, the DHA that lack in the body.

Claims (3)

1. compound vitamin drop for infant is characterized in that described drop comprises:
Vitamin A 300-1500
Vitamin D 200-500
DHA(mg)?????40-150
GLA(mg)?????60-160
Vitamin E (mg) 0.1-4.0
2. compound vitamin drop for infant is characterized in that described soft capsule drop comprises: every seed lac ball loading amount 0.5-0.7ml mixotrophism oil, wherein: Radix Oenotherae erythrosepalae oil or with GLA oil V A150~750l μ Oleum Radix Arnebiae (Oleum Radix Lithospermi) mixes 60~80% 250~1000l μ fish oil, 10~30% V D100~300l μ Oleum Hippophae, 0~10% V E0.05~2.0mg
3. compound vitamin drop for infant is characterized in that described soft capsule O/W type Emulsion comprises:
Prescription: V A, V DUnsaturated fatty acid miscella 1~10%;
90-99% such as high fructose syrup, fruit juice, thickening agent, emulsifying agent;
Radix Oenotherae erythrosepalae oil in the miscella (or mix with Oleum Radix Arnebiae (Oleum Radix Lithospermi), soybean oil, GLA oil) 60~80%;
Fish oil 10~30%; Oleum Hippophae 0~10%.
CN96109176A 1996-08-15 1996-08-15 Compound vitamin drop for infant Expired - Fee Related CN1094348C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN96109176A CN1094348C (en) 1996-08-15 1996-08-15 Compound vitamin drop for infant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN96109176A CN1094348C (en) 1996-08-15 1996-08-15 Compound vitamin drop for infant

Publications (2)

Publication Number Publication Date
CN1174032A true CN1174032A (en) 1998-02-25
CN1094348C CN1094348C (en) 2002-11-20

Family

ID=5120278

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96109176A Expired - Fee Related CN1094348C (en) 1996-08-15 1996-08-15 Compound vitamin drop for infant

Country Status (1)

Country Link
CN (1) CN1094348C (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102217753A (en) * 2010-04-16 2011-10-19 光明乳业股份有限公司 Mixed grease composition suitable for infant formula food and preparation method and application thereof
CN106262934A (en) * 2016-08-19 2017-01-04 朱路 A kind of infant is combined AD preparation
CN109619214A (en) * 2019-01-15 2019-04-16 广州富诺健康科技股份有限公司 A kind of mushroom oil droplet agent and preparation method thereof rich in vegetalitas VD2
CN110339162A (en) * 2019-07-24 2019-10-18 杭州海王生物工程有限公司 A kind of vitamins drops and preparation method thereof
CN111602820A (en) * 2020-05-28 2020-09-01 广州富诺营养科技有限公司 Drop containing vitamin A and vitamin D and its preparation method

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102217753A (en) * 2010-04-16 2011-10-19 光明乳业股份有限公司 Mixed grease composition suitable for infant formula food and preparation method and application thereof
CN106262934A (en) * 2016-08-19 2017-01-04 朱路 A kind of infant is combined AD preparation
CN109619214A (en) * 2019-01-15 2019-04-16 广州富诺健康科技股份有限公司 A kind of mushroom oil droplet agent and preparation method thereof rich in vegetalitas VD2
CN110339162A (en) * 2019-07-24 2019-10-18 杭州海王生物工程有限公司 A kind of vitamins drops and preparation method thereof
CN111602820A (en) * 2020-05-28 2020-09-01 广州富诺营养科技有限公司 Drop containing vitamin A and vitamin D and its preparation method

Also Published As

Publication number Publication date
CN1094348C (en) 2002-11-20

Similar Documents

Publication Publication Date Title
DE60033233T2 (en) FOOD SUPPLEMENTS
US20020044961A1 (en) Nutritional formulations
EP2459013B1 (en) Food composition for lactating women
US20030216351A1 (en) Nutritional supplements
JP2008519796A (en) Nutrients containing lipid mixture
EP3804700A1 (en) Methods, compositions, and devices for supplying dietary fatty acid needs
CN1960715A (en) Nutritional formulations
CN101259102A (en) Micrometre level docosahexaenoic acid emulsion and preparation thereof
CN103687495A (en) Composition comprising vitamin k2
CN1853716A (en) Nutritive supplementary composition
JPH0394655A (en) Nutrient feeding composition
CN105432792A (en) Basic nutrition milk powder for preschool children, nutrition milk powder suit and preparation methods
CN1094348C (en) Compound vitamin drop for infant
CN101167793A (en) Walnut oil fat emulsion and manufacturing method thereof
CN1774179A (en) Multi-vitamin and mineral supplement for pregnant women
GB2459657A (en) Postnatal dietary supplement.
WO2007100562A2 (en) Use of dha and ara in the preparation of a composition for reducing triglyceride levels
Carroll Upper limits of nutrients in infant formulas: polyunsaturated fatty acids and trans fatty acids
CN102511858A (en) Thickened red jujube pulp suitable for being taken by pregnant women and manufacturing technology of same
Park Human milk
CN101293998A (en) Method for preparing water-soluble nano-functional fatty acid complexes carrier
CN109601987A (en) A kind of microcapsule powder, wet nurse's nutrient supplement food and preparation method thereof
CN101816422A (en) Oenothera biennise oil fat emulsion oral solution, drink and preparation method thereof
CN102018763A (en) Linseed oil fat emulsion intravenous injection fluid and production method thereof
KR101090390B1 (en) Method of protected coating from dha

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee